The US Food and Drug Administration (FDA) approved a record number of generic drugs in July, highlighting the rapid growth in drug development. As drug prices around the world continue to rise, increased generic options challenge makers of more expensive brand-name drugs to find ways to cut the costs of drug development.
The trend of precision medicine is spreading across malignancies, targeting driver mutations to provide a tailored treatment approach. This is especially relevant in immunotherapy, as cancer remains one of the world’s top healthcare challenges, where this approach could dramatically extend expected survival rates. With an ageing and growing population, the number of cancer patients increases each year, many of whom will be waiting for and counting on the next big pharmaceutical breakthrough.
This article highlights the scope for developing therapeutics with new innovative, alternative approaches. The current trillion dollars pharmaceutical industry is in peril where the current drug development pipeline is slow, inefficient and incapable of being extended to multi-combination drug therapies as well as minimally focused on prevention. The complex modeling of diseases and biological functions has been limited because of the inability to integrate large scale molecular pathways.
Watch this Video to understand how recent advances provide breakthrough technology for doing scalable modeling of complex molecular systems to dramatically accelerate drug discovery and development.